BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | N022410 | INDIVIOR INC
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2016-01113 | 8475832 | IPR | Dr. Reddy’s Laboratories, Inc. et al. | Institution Denied | 2016-05-31 | — |
| IPR2016-00280 | 8475832 | IPR | Teva Pharmaceuticals USA, Inc. | Institution Denied | 2015-12-03 | — |
| IPR2014-00998 | 8475832 | IPR | BioDelivery Sciences International, Inc. | Institution Denied | 2014-06-20 | — |
| IPR2014-00325 | 8475832 | IPR | BioDelivery Sciences International, Inc. | Final Written Decision | 2014-01-15 | — |
| IPR2019-00328 | 9687454 | IPR | Dr. Reddy's Laboratories S.A. et al. | Institution Denied | 2018-11-13 | — |
| IPR2019-00329 | 9687454 | IPR | Dr. Reddy’s Laboratories S.A. et al. | Final Written Decision | 2018-11-13 | 2022-09-23 |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Indivior Inc. et al v. Actavis Laboratories UT, Inc. 1 patentANDA 204383, 207087buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2018-04-03 | Terminated 2019-09-16 | — |
Indivior et al v. Actavis Laboratories UT 2 patentsANDA 204383, 207087buprenorphine hydrochloride and naloxone hydrochloride | UTD | 2018-02-07 | Terminated 2018-05-03 | — |
Par Pharmaceutical, Inc. v. Indivior Inc. et al 2 patentsANDA 205854buprenorphine and naloxone | VAED | 2017-11-13 | Terminated 2018-05-21 | — |
INDIVIOR INC. et al v. PAR PHARMACEUTICAL INC et al 1 patentANDA 205854buprenorphine hydrochloride and naloxone hydrochloride | D.N.J. | 2017-10-06 | Terminated 2018-05-21 | — |
INDIVIOR INC. et al v. ALVOGEN PINE BROOK, INC. 1 patentANDA 205954buprenorphine hydrochloride and naloxone hydrochloride | D.N.J. | 2017-09-14 | Terminated 2023-11-09 | — |
INDIVIOR INC. et al v. TEVA PHARMACEUTICALS USA, INC. 1 patentbuprenorphine hydrochloride and naloxone hydrochloride | D.N.J. | 2017-09-14 | Terminated 2024-01-31 | — |
Indivior Inc. et al v. Teva Pharmaceuticals USA, Inc. 5 patentsANDA 205299, 205806buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2016-03-21 | Terminated 2019-09-05 | — |
Reckitt Benckiser Pharmaceuticals Inc. et al v. Par Pharmaceutical Inc. et al 5 patentsANDA 205854buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2014-12-31 | Terminated 2017-09-20 | — |
Reckitt Benckiser Pharmaceuticals Inc. et al v. Watson Laboratories Inc. et al. 2 patentsANDA 204383buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2014-12-31 | Terminated 2019-10-01 | — |
Indivior, Inc. et al v. Dr. Reddy's Laboratories S.A., et al. 3 patentsANDA 205806buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2014-12-02 | Terminated 2019-09-05 | — |
Reckitt Benckiser Pharmaceuticals Inc. et al v. Par Pharmaceutical Inc. et al 3 patentsANDA 020-5854buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2014-04-04 | Terminated 2019-09-05 | — |
Reckitt Benckiser Pharmaceuticals Inc. et al v. Par Pharmaceutical Inc. et al 2 patentsANDA 205854buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2013-08-20 | Terminated 2014-05-27 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).